Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC

Published Date: 08 Sep 2025

Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advances in "next generation" photoactive cancer therapy

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot